【摘 要】
：
Dr.Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China,Hong Kong,& Taiwan) at Merck & Co.,Inc.,USA.She is responsible for identifying and developing opportunities relat
【机 构】
：
Licensing & External Research(Mainland China,Hong Kong,& Taiwan)Merck & Co.USA
【出 处】
：
中国上海第七届国际新药发明科技年会
论文部分内容阅读
Dr.Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China,Hong Kong,& Taiwan) at Merck & Co.,Inc.,USA.She is responsible for identifying and developing opportunities related to partnership,licensing-in,and acquisition for new drug candidates and technologies for drug discovery and development in Mainland China,Hong Kong,and Taiwan.Prior to joining Merck & Co.,Inc.,Dr.Hu spent over three years with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics.Prior to that,she worked at Affymetrix in various capacities,including as Program Manager of Toxicology/Pharmacogenomics,establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application ofAffymetrix GeneChip technology.She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program.
其他文献
An understanding of structural geometry and the nature of intermolecular interactions is often important for the efficient design or selection of drug candidates for synthesis or testing.Therefore eas
The skyrocketing cost for drug development requires pharmaceutical and biotech industry to increase the possibility of success for their drug development candidates in the later stage of their develop
Transmembrane transporters (in short,transporters) move hydrophilic substrates across hydrophobic biological membranes and play key roles in nutrition intake,metabolism,signaling in living cells.There
Purpose:Advanced,castration-resistant prostate cancer,for which there are few treatment options,remains one of the leading causes of cancer death.MicroRNAs (miRNAs) have provided a new opportunity for
MicroRNAs (miRNAs) contains 18-24 nucleotides,which are often linked as clusters transcribed from genomic DNAs.The miR-17~92 is the most extensively studied cluster.This cluster and its paralogs play
Schistosomiasis causes liver and intestinal damage and can be very debilitating.The pairing of a male worm with a female worm residing in the gynaecophoral canal of male plays a critical role in the d
A live cell profiling approach for real-time monitoring and profiling of small molecules compounds will be described.The non-invasive readout allows continuous monitoring of cells inside the wells pro
Up-regulation ofproinflammatory cytokines by activated macrophages (Mψ) has been shown to drive the pathogenesis of several rheumatic diseases including rheumatoid arthritis,chronic plaque psoriasis,a
1.Opportunity.Pharmaceutical markets development have slowed to 2.5%-3.5%; and revenue growth is softening most in those countries where a high portion of drug costs are self-paid,such as the U.S.,Chi
Current pre-clinical cancer animal models are poorly predictive in clinical efficacy,and have limited value in predicting disease indications in humans.Primary tumor tissue offers a valuable resource